Brief: Arcus Biosciences Says Data From Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Arcus Biosciences

16/01/2024 23:06

Jan 16 (Reuters) - Arcus Biosciences Inc  RCUS.N :
    * DATA FROM A PHASE 1B STUDY OF QUEMLICLUSTAT-BASED REGIMENS
SHOWED PROMISING OVERALL SURVIVAL IN TREATMENT-NAÏVE METASTATIC
PANCREATIC CANCER
    * ARCUS BIOSCIENCES : MEDIAN OVERALL SURVIVAL WAS 15.7
MONTHS FOR
ALL PATIENTS TREATED WITH 100 MG QUEMLICLUSTAT-BASED REGIMENS IN
ARC-8 STUDY
    * ARCUS BIOSCIENCES INC - A 37% REDUCTION IN RISK OF DEATH
AND A
5.9-MONTH IMPROVEMENT IN MEDIAN OVERALL SURVIVAL WAS OBSERVED IN
TRIAL
    * ARCUS BIOSCIENCES: PHASE 1B STUDY OF QUEMLICLUSTAT-BASED
REGIMENS SHOWED PROMISING OVERALL SURVIVAL IN TREATMENT-NAÏVE
METASTATIC PANCREATIC CANCER

Source text for Eikon:  ID:nBwKbl2Xa 
Further company coverage:  RCUS.N 

 ((Reuters.Briefs@thomsonreuters.com;))